Novartis Pharmaceuticals

Novartis Products

Pharmaceuticals

Innovating to treat disease more effectively

Our global Pharmaceuticals portfolio includes more than 50 key marketed products, many of which are innovative leaders in their therapeutic areas. In 2009 we received a total of 25 positive regulatory decisions in the United States, Europe and Japan.

Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.

Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.

Note that some product links are intended for US residents only.

Learn more about our Pharmaceuticals Division

View by therapeutic area

A-Z

A C D E F G I L M N P R S T V X Z

Lamisil (terbinafine)

Fungal infection of the skin and nails caused by dermatophyte fungi Tinea capitis.
Fungal infections of the skin for the treatment of tinea corporis, tinea cruris, tinea pedis and yeast infections of the skin caused by the genus Candida (e.g. Candida albicans)

Visit www.lamisil.com (US residents only)

Clozaril/Leponex (clozapine)

Treatment resistant schizophrenia
Prevention and treatment of recurrent suicidal behavior in patients with schizophrenia and schizoaffective disorder

Visit www.clozaril.com (US residents only)

Lescol/Lescol XL (fluvastatin sodium)

Hypercholesterolemia and mixed dyslipidemia in adults.
Secondary prevention of major adverse cardiac events. Slowing the progression of atherosclerosis.
Heterozygous familial hypercholesterolemia in children and adolescents.

Visit www.lescolxl.com (US residents only)

Lotensin/Cibacen (benazepril hydrochloride)